Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Howard

Showing results (51-60 of 131) with videos related to

Pageof 14
Sort By:
Journal of Neurology|March 8, 2023
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravisTuan Vu, Stephan Ortiz, Masahisa Katsuno, et al.
Journal of Clinical Apheresis|March 7, 2025
The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical CenterAshley J Crosby, Mariama Evans, Danielle L V Maracaja, et al.
Therapeutic Advances in Neurological Disorders|May 20, 2020
Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension studySaiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 21, 2011
Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophyZheng Fan, Keith Kocis, Robert Valley, et al.
Journal of Neurology|April 27, 2023
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extensionAndreas Meisel, Djillali Annane, Tuan Vu, et al.
Journal of the Neurological Sciences|August 14, 2025
First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumabJames F Howard, Dubravka Dodig, Lida Zeinali, et al.
Science Translational Medicine|October 30, 2024
Engineering CAR-T therapies for autoimmune disease and beyondEmily P English, Rachel N Swingler, Simran Patwa, et al.
Muscle & Nerve|February 21, 2024
Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG studyJames F Howard, Tuan Vu, Renato Mantegazza, et al.
Muscle & Nerve|September 22, 2009
Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committeePeter D Donofrio, Alan Berger, Thomas H Brannagan, et al.
Human Gene Therapy|May 9, 2015
High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% SalineZheng Fan, Keith Kocis, Robert Valley, et al.
Pageof 14

Showing results (51-60 of 131) with videos related to

Sort By:
Pageof 14
Journal of Neurology|March 8, 2023
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravisTuan Vu, Stephan Ortiz, Masahisa Katsuno, et al.
Journal of Clinical Apheresis|March 7, 2025
The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical CenterAshley J Crosby, Mariama Evans, Danielle L V Maracaja, et al.
Therapeutic Advances in Neurological Disorders|May 20, 2020
Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension studySaiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 21, 2011
Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophyZheng Fan, Keith Kocis, Robert Valley, et al.
Journal of Neurology|April 27, 2023
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extensionAndreas Meisel, Djillali Annane, Tuan Vu, et al.
Journal of the Neurological Sciences|August 14, 2025
First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumabJames F Howard, Dubravka Dodig, Lida Zeinali, et al.
Science Translational Medicine|October 30, 2024
Engineering CAR-T therapies for autoimmune disease and beyondEmily P English, Rachel N Swingler, Simran Patwa, et al.
Muscle & Nerve|February 21, 2024
Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG studyJames F Howard, Tuan Vu, Renato Mantegazza, et al.
Muscle & Nerve|September 22, 2009
Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committeePeter D Donofrio, Alan Berger, Thomas H Brannagan, et al.
Human Gene Therapy|May 9, 2015
High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% SalineZheng Fan, Keith Kocis, Robert Valley, et al.
Pageof 14